UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:CDK9_CDK9 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: CDK9_CDK9 | KinaseFusionDB ID: KFG1208 | FusionGDB2.0 ID: KFG1208 | Hgene | Tgene | Gene symbol | CDK9 | CDK9 | Gene ID | 1025 | 1025 | |
Gene name | cyclin dependent kinase 9 | cyclin dependent kinase 9 | ||||||||||
Synonyms | C-2k|CDC2L4|CTK1|PITALRE|TAK | C-2k|CDC2L4|CTK1|PITALRE|TAK | ||||||||||
Cytomap | 9q34.11 | 9q34.11 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | cyclin-dependent kinase 9CDC2-related kinasecell division cycle 2-like protein kinase 4cell division protein kinase 9serine/threonine protein kinase PITALREtat-associated kinase complex catalytic subunit | cyclin-dependent kinase 9CDC2-related kinasecell division cycle 2-like protein kinase 4cell division protein kinase 9serine/threonine protein kinase PITALREtat-associated kinase complex catalytic subunit | ||||||||||
Modification date | 20240416 | 20240416 | ||||||||||
UniProtAcc | P50750 | P50750 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000373264, ENST00000373265, ENST00000480353, | ENST00000373264, ENST00000373265, ENST00000480353, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: CDK9 [Title/Abstract] AND CDK9 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CDK9(130552230)-CDK9(130552082), # samples:1 CDK9(130552004)-CDK9(130552084), # samples:1 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | CDK9 | GO:0006282 | regulation of DNA repair | 20493174 |
Hgene | CDK9 | GO:0006366 | transcription by RNA polymerase II | 28426094 |
Hgene | CDK9 | GO:0006468 | protein phosphorylation | 16109376 |
Hgene | CDK9 | GO:0031297 | replication fork processing | 20930849 |
Hgene | CDK9 | GO:0032968 | positive regulation of transcription elongation by RNA polymerase II | 9499409|14701750|30134174 |
Hgene | CDK9 | GO:0043923 | positive regulation by host of viral transcription | 10866664 |
Hgene | CDK9 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 29335245 |
Hgene | CDK9 | GO:0051647 | nucleus localization | 12942536 |
Hgene | CDK9 | GO:0051726 | regulation of cell cycle | 20930849 |
Hgene | CDK9 | GO:0071345 | cellular response to cytokine stimulus | 17956865 |
Hgene | CDK9 | GO:0120186 | negative regulation of protein localization to chromatin | 14701750 |
Hgene | CDK9 | GO:0120187 | positive regulation of protein localization to chromatin | 29335245 |
Hgene | CDK9 | GO:0140673 | transcription elongation-coupled chromatin remodeling | 19844166 |
Tgene | CDK9 | GO:0006282 | regulation of DNA repair | 20493174 |
Tgene | CDK9 | GO:0006366 | transcription by RNA polymerase II | 28426094 |
Tgene | CDK9 | GO:0006468 | protein phosphorylation | 16109376 |
Tgene | CDK9 | GO:0031297 | replication fork processing | 20930849 |
Tgene | CDK9 | GO:0032968 | positive regulation of transcription elongation by RNA polymerase II | 9499409|14701750|30134174 |
Tgene | CDK9 | GO:0043923 | positive regulation by host of viral transcription | 10866664 |
Tgene | CDK9 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 29335245 |
Tgene | CDK9 | GO:0051647 | nucleus localization | 12942536 |
Tgene | CDK9 | GO:0051726 | regulation of cell cycle | 20930849 |
Tgene | CDK9 | GO:0071345 | cellular response to cytokine stimulus | 17956865 |
Tgene | CDK9 | GO:0120186 | negative regulation of protein localization to chromatin | 14701750 |
Tgene | CDK9 | GO:0120187 | positive regulation of protein localization to chromatin | 29335245 |
Tgene | CDK9 | GO:0140673 | transcription elongation-coupled chromatin remodeling | 19844166 |
Kinase Fusion gene breakpoints across CDK9 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across CDK9 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChiTaRS5.0 | BF751344 | CDK9 | chr9 | 130552230 | CDK9 | chr9 | 130552082 |
ChiTaRS5.0 | BI024596 | CDK9 | chr9 | 130552004 | CDK9 | chr9 | 130552084 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:130552230/:130552082) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
CDK9 | CDK9 |
FUNCTION: Protein kinase involved in the regulation of transcription (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094, PubMed:29335245). Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094, PubMed:30134174). This complex is inactive when in the 7SK snRNP complex form (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094). Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR and the negative elongation factors DSIF and NELFE (PubMed:9857195, PubMed:10912001, PubMed:11112772, PubMed:12037670, PubMed:20081228, PubMed:20980437, PubMed:21127351). Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling) (PubMed:17956865, PubMed:18362169). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis (PubMed:10393184, PubMed:11112772). P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export (PubMed:15564463, PubMed:19575011, PubMed:19844166). Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing (PubMed:15564463, PubMed:19575011, PubMed:19844166). The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed:21127351). Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage (PubMed:20493174). In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6 (PubMed:20493174). Promotes cardiac myocyte enlargement (PubMed:20081228). RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription (PubMed:21127351). AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect (PubMed:9857195, PubMed:10912001, PubMed:11112772). The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation (PubMed:12037670). Catalyzes phosphorylation of KAT5, promoting KAT5 recruitment to chromatin and histone acetyltransferase activity (PubMed:29335245). {ECO:0000269|PubMed:10393184, ECO:0000269|PubMed:10574912, ECO:0000269|PubMed:10757782, ECO:0000269|PubMed:10912001, ECO:0000269|PubMed:11112772, ECO:0000269|PubMed:11145967, ECO:0000269|PubMed:11575923, ECO:0000269|PubMed:11809800, ECO:0000269|PubMed:11884399, ECO:0000269|PubMed:12037670, ECO:0000269|PubMed:14701750, ECO:0000269|PubMed:15564463, ECO:0000269|PubMed:16109376, ECO:0000269|PubMed:16109377, ECO:0000269|PubMed:17956865, ECO:0000269|PubMed:18362169, ECO:0000269|PubMed:19575011, ECO:0000269|PubMed:19844166, ECO:0000269|PubMed:20081228, ECO:0000269|PubMed:20493174, ECO:0000269|PubMed:20930849, ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:21127351, ECO:0000269|PubMed:28426094, ECO:0000269|PubMed:29335245, ECO:0000269|PubMed:30134174, ECO:0000269|PubMed:9857195}. | FUNCTION: Protein kinase involved in the regulation of transcription (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094, PubMed:29335245). Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094, PubMed:30134174). This complex is inactive when in the 7SK snRNP complex form (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094). Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR and the negative elongation factors DSIF and NELFE (PubMed:9857195, PubMed:10912001, PubMed:11112772, PubMed:12037670, PubMed:20081228, PubMed:20980437, PubMed:21127351). Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling) (PubMed:17956865, PubMed:18362169). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis (PubMed:10393184, PubMed:11112772). P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export (PubMed:15564463, PubMed:19575011, PubMed:19844166). Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing (PubMed:15564463, PubMed:19575011, PubMed:19844166). The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed:21127351). Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage (PubMed:20493174). In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6 (PubMed:20493174). Promotes cardiac myocyte enlargement (PubMed:20081228). RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription (PubMed:21127351). AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect (PubMed:9857195, PubMed:10912001, PubMed:11112772). The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation (PubMed:12037670). Catalyzes phosphorylation of KAT5, promoting KAT5 recruitment to chromatin and histone acetyltransferase activity (PubMed:29335245). {ECO:0000269|PubMed:10393184, ECO:0000269|PubMed:10574912, ECO:0000269|PubMed:10757782, ECO:0000269|PubMed:10912001, ECO:0000269|PubMed:11112772, ECO:0000269|PubMed:11145967, ECO:0000269|PubMed:11575923, ECO:0000269|PubMed:11809800, ECO:0000269|PubMed:11884399, ECO:0000269|PubMed:12037670, ECO:0000269|PubMed:14701750, ECO:0000269|PubMed:15564463, ECO:0000269|PubMed:16109376, ECO:0000269|PubMed:16109377, ECO:0000269|PubMed:17956865, ECO:0000269|PubMed:18362169, ECO:0000269|PubMed:19575011, ECO:0000269|PubMed:19844166, ECO:0000269|PubMed:20081228, ECO:0000269|PubMed:20493174, ECO:0000269|PubMed:20930849, ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:21127351, ECO:0000269|PubMed:28426094, ECO:0000269|PubMed:29335245, ECO:0000269|PubMed:30134174, ECO:0000269|PubMed:9857195}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of CDK9_CDK9 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
CDK9 | P50750 | human | SIRT1 | Q96EB6 | S47 | DGPGLERsPGEPGGA | |
CDK9 | P50750 | human | ACTL6A | O96019 | S233 | kEAVREGsPANWkRk | Actin |
CDK9 | P50750 | human | SMAD1 | Q15797 | S195 | PNSSYPNsPGSSSSt | |
CDK9 | P50750 | human | SMAD1 | Q15797 | S187 | NSHPFPHsPNSSYPN | |
CDK9 | P50750 | human | CDK9 | P50750 | T186 | NSQPNRYtNRVVTLW | Pkinase |
CDK9 | P50750 | human | OGFOD1 | Q8N543 | S256 | FEPPIPRsPHIPQDH | |
CDK9 | P50750 | human | TP73 | O15350 | T86 | AASASPYtPEHAASV | |
CDK9 | P50750 | human | SUPT5H | O00267 | T784 | MyGsGsrtPMyGsQt | |
CDK9 | P50750 | human | H1-1 | Q02539 | S183 | KPKKVAKsPAKAKAV | |
CDK9 | P50750 | human | POLR2A | P24928 | T1525 | TPWNQGAtPAYGAWS | |
CDK9 | P50750 | human | BORA | Q6PGQ7 | S325 | sPYIDGCsPIKNWsP | |
CDK9 | P50750 | human | SUPT5H | O00267 | T775 | tPMyGsQtPMyGsGs | |
CDK9 | P50750 | human | PPARG | P37231 | S112 | AIkVEPAsPPYYSEK | |
CDK9 | P50750 | human | CDK9 | P50750 | S353 | GsQItQQstNQsRNP | |
CDK9 | P50750 | human | SUPT5H | O00267 | T768 | MtStyGRtPMyGsQt | |
CDK9 | P50750 | human | SMAD1 | Q15797 | S206 | SSStYPHsPTSSDPG | |
CDK9 | P50750 | human | RB1 | P06400 | S795 | sPykFPssPLrIPGG | Rb_C |
CDK9 | P50750 | human | TP53 | P04637 | S392 | FktEGPDsD______ | |
CDK9 | P50750 | human | TP53 | P04637 | S33 | LPENNVLsPLPsQAM | |
CDK9 | P50750 | human | CDK9 | P50750 | T363 | QsRNPAttNQtEFEr | |
CDK9 | P50750 | human | NCOA2 | Q15596 | S487 | GQPTSMLsPrHRMsP | NCOA_u2 |
CDK9 | P50750 | human | SMAD1 | Q15797 | S214 | PTSSDPGsPFQMPAD | |
CDK9 | P50750 | human | SMAD3 | P84022 | T179 | PQSNIPEtPPPGYLS | |
CDK9 | P50750 | human | SMAD3 | P84022 | S213 | NLsPNPMsPAHNNLD | |
CDK9 | P50750 | human | H1-4 | P10412 | S187 | KPKKAPKsPAKAkAV | |
CDK9 | P50750 | human | SUPT5H | O00267 | T814 | PLHDGsRtPAQsGAW | |
CDK9 | P50750 | human | RCHY1 | Q96PM5 | T217 | PsEYQNMtVDILCND | zinc_ribbon_6 |
CDK9 | P50750 | human | SMAD3 | P84022 | S208 | DAGsPNLsPNPMsPA | |
CDK9 | P50750 | human | RCHY1 | Q96PM5 | S211 | VAQTPMPsEYQNMtV | zinc_ribbon_6 |
CDK9 | P50750 | human | MDM2 | Q00987 | S166 | SsRRRAIsEtEENsD | |
CDK9 | P50750 | human | SUPT5H | O00267 | T806 | tPHyGsQtPLHDGsR | |
CDK9 | P50750 | human | POLR2A | P24928 | S1616 | TPQSPSysPtsPsYS | RNA_pol_Rpb1_R |
CDK9 | P50750 | human | XRN2 | Q9H0D6 | T439 | FtPsGILtPHALGsR | XRN_M |
CDK9 | P50750 | human | CDK9 | P50750 | T362 | NQsRNPAttNQtEFE | |
CDK9 | P50750 | human | SUPT5H | O00267 | T799 | PLQDGsRtPHyGsQt | |
CDK9 | P50750 | human | SUPT5H | O00267 | S782 | tPMyGsGsrtPMyGs | |
CDK9 | P50750 | human | SUPT5H | O00267 | S773 | GRtPMyGsQtPMyGs | |
CDK9 | P50750 | human | POLR2A | P24928 | S1621 | SysPtsPsYSPTSPS | RNA_pol_Rpb1_R |
CDK9 | P50750 | human | SUPT5H | O00267 | T791 | tPMyGsQtPLQDGsR | |
CDK9 | P50750 | human | MED1 | Q15648 | T1032 | SSSNRPFtPPTsTGG | |
CDK9 | P50750 | human | AR | P10275 | S83 | QQQQQETsPRQQQQQ | Androgen_recep |
CDK9 | P50750 | human | POLR2A | P24928 | T1618 | QSPSysPtsPsYSPT | RNA_pol_Rpb1_R |
CDK9 | P50750 | human | NCOA2 | Q15596 | S493 | LsPrHRMsPGVAGsP | NCOA_u2 |
CDK9 | P50750 | human | POLR2A | P24928 | T1540 | PSVGSGMtPGAAGFS | |
CDK9 | P50750 | human | POLR2A | P24928 | S1619 | SPSysPtsPsYSPTS | RNA_pol_Rpb1_R |
CDK9 | P50750 | human | SUPT5H | O00267 | S666 | VGGFAPMsPrISsPM | |
CDK9 | P50750 | human | ACTL6A | O96019 | S195 | LQQGIVksPLAGDFI | Actin |
CDK9 | P50750 | human | ACTL6A | O96019 | S86 | RENMEAIsPLkNGMV | Actin |
CDK9 | P50750 | human | RB1 | P06400 | S807 | PGGNIyIsPLksPyk | Rb_C |
CDK9 | P50750 | human | CDK9 | P50750 | S347 | APPRRkGsQItQQst | |
CDK9 | P50750 | human | AFF4 | Q9UHB7 | S388 | KDDLKLsssEDsDGE | AF-4 |
CDK9 | P50750 | human | NCOA2 | Q15596 | S499 | MsPGVAGsPrIPPSQ | NCOA_u2 |
CDK9 | P50750 | human | RB1 | P06400 | S811 | IyIsPLksPykIsEG | Rb_C |
CDK9 | P50750 | human | TP53 | P04637 | S315 | LPNNtsssPQPkkkP | |
CDK9 | P50750 | human | NCOA2 | Q15596 | S469 | NYALKMNsPsQSsPG | NCOA_u2 |
CDK9 | P50750 | human | CDK9 | P50750 | T354 | sQItQQstNQsRNPA |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
CDK9 | ID | Description | 0.00e+00 |
CDK9 | GO:1902895 | positive regulation of miRNA transcription | 4.86e-06 |
CDK9 | GO:2000630 | positive regulation of miRNA metabolic process | 4.86e-06 |
CDK9 | GO:0035357 | peroxisome proliferator activated receptor signaling pathway | 4.86e-06 |
CDK9 | GO:1902893 | regulation of miRNA transcription | 4.86e-06 |
CDK9 | GO:0061614 | miRNA transcription | 4.86e-06 |
CDK9 | GO:2000628 | regulation of miRNA metabolic process | 1.07e-05 |
CDK9 | GO:0140747 | regulation of ncRNA transcription | 1.29e-05 |
CDK9 | GO:0010586 | miRNA metabolic process | 2.20e-05 |
CDK9 | GO:1904179 | positive regulation of adipose tissue development | 2.71e-05 |
CDK9 | GO:0009299 | mRNA transcription | 4.57e-05 |
CDK9 | GO:0098781 | ncRNA transcription | 5.81e-05 |
CDK9 | GO:0061448 | connective tissue development | 8.48e-05 |
CDK9 | GO:1904177 | regulation of adipose tissue development | 8.71e-05 |
CDK9 | GO:0072332 | intrinsic apoptotic signaling pathway by p53 class mediator | 2.66e-04 |
CDK9 | GO:1901653 | cellular response to peptide | 3.26e-04 |
CDK9 | GO:0060333 | type II interferon-mediated signaling pathway | 3.26e-04 |
CDK9 | GO:0050678 | regulation of epithelial cell proliferation | 4.62e-04 |
CDK9 | GO:0007179 | transforming growth factor beta receptor signaling pathway | 4.62e-04 |
CDK9 | GO:0065004 | protein-DNA complex assembly | 5.50e-04 |
CDK9 | GO:1902253 | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 6.52e-04 |
CDK9 | GO:0043516 | regulation of DNA damage respons | 1.13e-05 |
CDK9 | GO:0071560 | cellular response to transforming growth factor beta stimulus | 1.08e-03 |
CDK9 | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 1.09e-03 |
CDK9 | GO:0071559 | response to transforming growth factor beta | 1.10e-03 |
CDK9 | GO:0001666 | response to hypoxia | 1.11e-03 |
CDK9 | GO:0042789 | mRNA transcription by RNA polymerase II | 1.11e-03 |
CDK9 | GO:0035196 | miRNA processing | 1.14e-03 |
CDK9 | GO:0071456 | cellular response to hypoxia | 1.19e-03 |
CDK9 | GO:0071375 | cellular response to peptide hormone stimulus | 1.20e-03 |
CDK9 | GO:0036293 | response to decreased oxygen levels | 1.25e-03 |
CDK9 | GO:0036294 | cellular response to decreased oxygen levels | 1.43e-03 |
CDK9 | GO:0017015 | regulation of transforming growth factor beta receptor signaling pathway | 1.43e-03 |
CDK9 | GO:0048545 | response to steroid hormone | 1.43e-03 |
CDK9 | GO:0051147 | regulation of muscle cell differentiation | 1.43e-03 |
CDK9 | GO:1903844 | regulation of cellular response to transforming growth factor beta stimulus | 1.43e-03 |
CDK9 | GO:0060612 | adipose tissue development | 1.54e-03 |
CDK9 | GO:0070482 | response to oxygen levels | 1.54e-03 |
CDK9 | GO:0045862 | positive regulation of proteolysis | 1.58e-03 |
CDK9 | GO:0050680 | negative regulation of epithelial cell proliferation | 1.58e-03 |
CDK9 | GO:0071453 | cellular response to oxygen levels | 1.58e-03 |
CDK9 | GO:0030522 | intracellular receptor signaling pathway | 1.58e-03 |
CDK9 | GO:0072331 | signal transduction by p53 class mediator | 1.58e-03 |
CDK9 | GO:0032786 | positive regulation of DNA-templated transcriptio | 4.97e-05 |
CDK9 | GO:0014745 | negative regulation of muscle adaptation | 1.83e-03 |
CDK9 | GO:0043353 | enucleate erythrocyte differentiation | 1.83e-03 |
CDK9 | GO:0009755 | hormone-mediated signaling pathway | 2.08e-03 |
CDK9 | GO:0033148 | positive regulation of intracellular estrogen receptor signaling pathway | 2.08e-03 |
CDK9 | GO:0051095 | regulation of helicase activity | 2.08e-03 |
CDK9 | GO:0071479 | cellular response to ionizing radiation | 2.08e-03 |
Top |
Related Drugs to CDK9_CDK9 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning CDK9-CDK9 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to CDK9_CDK9 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |